Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions (Q33929699)

30 July 2017

1 reference

title

Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions (English)

1 reference

30 July 2017

1 reference

3

M B Stern

1 reference

30 July 2017

A D Siderowf

1

1 reference

30 July 2017

R G Holloway

series ordinal

2

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

15

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

439-445

1 reference

The changing US health care system: challenges for responsible public policy

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

Health care policy: a clinical approach. Mechanisms for controlling costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

High-priced technology can be good value for money.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

Clinical economics. A guide to the economic analysis of clinical practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

A clinician's guide to cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

Confidence intervals for cost-effectiveness ratios: a comparison of four methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

The health burdens of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

Risk factors for nursing home placement in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

The epidemiology, clinical characteristics, and natural history of older nursing home residents with a diagnosis of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

Cost effectiveness of pramipexole in Parkinson's disease in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

Qualitative comparison of the reliability of health status assessments with the EuroQol and SF-36 questionnaires after stroke. United Kingdom Collaborators in the International Stroke Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

Variability in length of hospitalization for stroke. The role of managed care in an elderly population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

What role do neurologists play in determining the costs and outcomes of stroke patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

Echocardiographic identification of cardiovascular sources of emboli to guide clinical management of stroke: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

Cost-Effectiveness of Screening for Carotid Stenosis in Asymptomatic Persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

National health expenditures in 1997: more slow growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

Family caregiving: a neglected and hidden part of health care delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

Costs of drug treatment in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

The Burden of Parkinson's Disease on Society, Family, and the Individual

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

The Impact of Parkinson??s Disease on Health Status, Health Expenditures, and Productivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

Epidemiology of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

Treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

The impact of new pharmaceutical agents on the cost of neurologic care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C439%3A%3AAID-MDS1004%3E3.0.CO%3B2-F

10.1002/1531-8257(200005)15:3<439::AID-MDS1004>3.0.CO;2-F

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference